ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NVAX Novavax Inc

12.26
-0.64 (-4.96%)
Pre Market
Last Updated: 12:23:56
Delayed by 15 minutes
Share Name Share Symbol Market Type
Novavax Inc NASDAQ:NVAX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.64 -4.96% 12.26 12.26 12.27 135,193 12:23:56

Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results on February 27, 2017

20/02/2017 9:05pm

GlobeNewswire Inc.


Novavax (NASDAQ:NVAX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Novavax Charts.

Novavax, Inc. (Nasdaq:NVAX) today announced it will report its fourth quarter and full year 2016 financial and operating results following the close of U.S. financial markets on Monday, February 27, 2017.

Conference call details are as follows:

Date: Monday, February 27, 2017
Time: 4:30 p.m. U.S. Eastern Time (ET)
Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode: 61206704
Webcast: www.novavax.com, “Investors”/ “Events”
   

Conference call and webcast replay:

Dates: Starting at 7:30 p.m. ET, February 27, 2017, until midnight March 3, 2017
Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode: 61206704
Webcast: www.novavax.com, “Investors”/ “Events”, until April 30, 2017
   

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Contact:

Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations
ir@novavax.com
240-268-2000

Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
david.schull@russopartnersllc.com 
212-845-4271

1 Year Novavax Chart

1 Year Novavax Chart

1 Month Novavax Chart

1 Month Novavax Chart

Your Recent History

Delayed Upgrade Clock